Factorial Partners’s AstraZeneca AZN Stock Holding History

Factorial Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,500	Closed	-$119K	–	123
2018 Q3	$119K	Buy	+1,500	New	+$113K	0.1%	95
2018 Q2	–	Sell	-17,950	Closed	-$1.26M	–	102
2018 Q1	$1.26M	Buy	17,950 +1,750	+11%	+$121K	1.15%	30
2017 Q4	$1.12M	Buy	+16,200	New	+$1.09M	1.04%	32

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Factorial Partners's AZN Position: Q4 2018 in Review

Factorial Partners sold out of AstraZeneca (AZN) in Q4 2018, closing a stake of 1,500 shares — an estimated $119K sold.

Factorial Partners first reported a position in AZN in Q4 2017 and held it in 3 quarters. The position peaked at $1.26M in Q1 2018. 557 funds tracked by Wall St. Rank hold AZN as of Q4 2018.

Factorial Partners reported no remaining AstraZeneca position as of Q4 2018 after selling out during the quarter.
Factorial Partners sold 1,500 AstraZeneca shares in Q4 2018, an estimated $119K.
Factorial Partners first reported a position in AstraZeneca in Q4 2017 and held it in 3 quarters.
Factorial Partners's AstraZeneca position peaked at $1.26M in Q1 2018.
557 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2018.

Based on Factorial Partners's 13F filing for Q4 2018, filed 14 Feb 2019.